FDA updates its guidance, potentially enabling broader adoption of LLM-based clinical decision support software in radiology.
Key Details
- 1FDA released updated guidance on regulating clinical decision-support (CDS) software as a medical device in January 2024.
- 2The new guidance clarifies that certain LLM and CDS tools that do not directly analyze images may be exempt from device regulation if they meet four specific criteria.
- 3Previously, tools generating diagnostic text recommendations or risk predictions were typically regulated as medical devices.
- 4The updated interpretation may open opportunities for more LLM-based applications to assist radiologists without requiring full FDA device approval, provided clinicians retain review authority.
- 5Image-analyzing AI (such as CAD or denoising tools) remains regulated as medical devices.
Why It Matters
This policy shift could accelerate development and clinical adoption of text-based AI assistants and reporting tools in radiology, reducing regulatory barriers. Clarity from the FDA also helps innovators and healthcare providers assess which AI-driven software must undergo formal device review.
Source
AuntMinnie
Related News
•Radiology Business
Radiology Partners Urges FDA for Clarity on Imaging AI Regulations
Radiology Partners and Mosaic Clinical Technologies petition the FDA for clearer regulatory guidelines on imaging AI vision-language models.
•Radiology Business
FDA Solicits Public Input on Regulating Generative AI in Medical Devices
The FDA is seeking public feedback on how to regulate generative AI in medical devices, recognizing both its promise and risks.
•HealthExec
AI's Role in Eliminating Cervical Cancer: A Model for Disease Prevention
Researchers highlight how AI can accelerate the elimination of cervical cancer and set a precedent for combating other diseases.